ライフサイエンスコーパス: PET

1 PET amyloid data were obtained with 18F-flutemetamol (Vi

2 PET findings were compared between the 2 radiotracers an

3 PET images showed focal myocardial (18)F-FOL uptake colo

4 PET images were reconstructed with 4-mm voxels and 2-mm

5 PET imaging identified significantly higher left ventric

6 PET using O-(2-(18)F-fluoroethyl)-l-tyrosine ((18)F-FET)

7 PET was associated with a 10% lower absolute rate of CMV

8 PET-2 was classified according to both 5-PS and percenta

9 PET/MR (18)F-FAC images showed a 12% increase in tumor (

10 s: All (18)F-fluciclovine and (68)Ga-PSMA-11 PET studies performed at the University of California Sa

11 body (from vertex to toes) in (68)Ga-PSMA-11 PET/CT imaging revealed additional bone lesions in 6% of

12 , patients with corresponding (68)Ga-PSMA-11 PET/CT scans were matched.

13 s and bone metastases in 5 on (68)Ga-PSMA-11 PET/MRI.

14 vivo tau pathology (measured by 18F-AV-1451 PET), neuroinflammation (measured by 11C-PK11195 PET) an

15 nce and reduced energy expenditure and 18FDG-PET uptake in brown adipose tissue.

16 sistence), 4 of 16 had new lesions only (25% PET recurrence), and 2 had no disease on post-SLND PET.

17 lly, for 5 patients who completed at least 3 PET/CT scans after administration of (124)I-MIBG, we est

18 thy male volunteers received [(11)C]CIMBI-36 PET scans before and 3 h after an oral dose of d-ampheta

19 one lesion already detected at baseline (63% PET persistence), 4 of 16 had new lesions only (25% PET

20 o investigate the efficacy of (18)F-rhPSMA-7 PET for primary N-staging of patients with prostate canc

21 specificity, and accuracy of (18)F-rhPSMA-7 PET were 53.8%, 96.9%, and 90.9%, respectively, and thos

22 Conclusion: (18)F-rhPSMA-7 PET/CT offers high PPV in BCR after RP.

23 oethyl)-L-tryptophan (1-L-[(18)F]FETrp) as a PET imaging probe for this common malignant pediatric br

24 labeled pH-targeted peptide can be used as a PET imaging tool to assess therapy response within PDAC

25 ns, showed excellent kinetic properties as a PET radioligand.

26 binds to K(V)1 channels and can be used as a PET tracer for the detection of demyelinated lesions in

27 tential use of (89)Zr-HDL nanoparticles as a PET tracer to quickly monitor the response to CSF1R inhi

28 Here, we present a PET biodistribution and radiation dosimetry study of (68

29 ied as AD dementia but having negative Abeta PET scans show little increase but plasma p-tau181 is in

30 significant correlation between AIs of Abeta PET and TSPO PET in 4 investigated Abeta mouse models (A

31 CSF Abeta has already changed prior to Abeta PET changes.

32 simultaneous fluorodihydroxyphenyl-l-alanine PET (18F-DOPA-PET) and resting state functional MRI (rs-

33 First, all PET-positive lesions were noted.

34 Amyloid PET, (18)F-FDG PET, and CSF test combinations may add ac

35 nger age (P = 0.02), higher baseline amyloid PET (P = 0.05), APOE epsilon4 (P = 0.05), and better cog

36 information equivalent to that from amyloid PET.

37 reached by combining (18)F-FDG PET, amyloid PET, and nonimaging variables.

38 bility to typical clinical settings, amyloid PET, (18)F-FDG PET, and MRI were highly sensitive for ne

39 stinct biomarker sequences, in which amyloid-PET and (18)F-FDG-PET are placed at different positions

40 high diagnostic performance when both CT and PET images are used.

41 om a retrospective analysis using PET/CT and PET/MRI examinations to investigate the efficacy of (18)

42 The concordance between CT- and PET-based criteria and the capability of each method to

43 the beneficial effect bioactive factors and PET incorporation have on ACL regeneration and signal a

44 rbon-11-labelled complex pharmaceuticals and PET radioligands, including a one-step radiosynthesis of

45 1 of 10 and 7 of 10 cases for PET/static and PET/matched, respectively.

46 city, and time between initial treatment and PET imaging was evaluated.

47 Small-animal PET imaging demonstrated high tumor uptake within 20 min

48 wn in preclinical evaluation by small-animal PET studies, organ distribution, and a patient applicati

49 rolled trial that compared valganciclovir as PET or prophylaxis for 100 days in 205 D+R- liver transp

50 a acquired from patient volunteers to assess PET quantitative bias in vivo.

51 inary study is a first step toward automated PET/CT assessment for lymphoma.(C) RSNA, 2020.

52 in Wistar rats by in vitro autoradiography, PET imaging, ex vivo biodistribution, metabolite experim

53 amyloid-beta positivity using (18)F-AZD4694 PET.

54 mpaired (n = 65)] who underwent amyloid-beta PET with (18)F-AZD4694, lumbar puncture, structural MRI,

55 imilar analysis on longitudinal amyloid-beta-PET (in ADNI subjects only, n = 639), we found significa

56 tudy was to examine the relationship between PET-CT derived tumour glucose uptake as measured by maxi

57 bio-based poly(ethylene terephthalate) (Bio-PET) substrates for the development of flexible electroc

58 During each imaging session, 9 whole-body PET scans were obtained at 5, 10, 20, 30, 40, 50, 60, 12

59 ell cancer, or leukemia underwent whole-body PET/CT imaging 90 min after injection of (18)F-SKI (mean

60 e data acquired on a conventional whole-body PET/CT system with a typical clinical protocol differed

61 le for a first response assessment with both PET- and CT-based criteria.

62 case suggests that (18)F-alpha(v)beta(6)-BP PET/CT is a promising noninvasive approach to identify t

63 stimates in tracer kinetic modeling in brain PET studies.

64 d dosimetry of (68)Ga-Tuna-2 was assessed by PET/CT in 13 individuals with type 2 diabetes as part of

65 The results were confirmed by PET, histology and ICPMS.

66 encing experiments such as ChIP-seq and ChIA-PET that generate coverage files for transcription facto

67 DNase-seq/ATAC-seq, P300, POLR2A, CAGE, ChIA-PET, GRO-seq, STARR-seq and MPRA).

68 E recovers a higher number of published ChIA-PET and HiChIP loops as well as loops linking promoters

69 t high-resolution 3D genome mapping via ChIA-PET to capture RNAPII-associated chromatin interactions

70 Conclusion: (11)C-choline PET/CT can detect PCa recurrence even among patients wit

71 The correlation between (11)C-choline PET/CT positivity and initial treatment, Gleason score,

72 he 2 readers deemed 66% of the (11)C-choline PET/CT scans as positive.

73 of suspicion for recurrence on (11)C-choline PET/CT was scored (0, negative; 1, equivocal; 2, positiv

74 on correction processing to emulate clinical PET/MRI.

75 ngitudinal PET-only studies, and comparative PET and autopsy studies are included.

76 Conclusion: PET with pulmonary administered (11)C-BMP can measure AB

77 ly with regional amyloid burden in congruent PET images.

78 Deep learning-corrected PET (PET(DL)) images were quantitatively evaluated by us

79 In line with its preclinical data, PET imaging resulted in clear visualization of the cance

80 Results: (18)F-DCFPyL PET/CT had an overall positivity rate of 85%, which incr

81 aluating the positivity rate of (18)F-DCFPyL PET/CT in patients with biochemical recurrence (BCR) of

82 Patients received 2 whole-body (18)F-DCFPyL PET/CT scans (median dose, 317 MBq; uptake time, 120 min

83 te the lesion detection rate of (18)F-DCFPyL PET/CT, a prostate-specific membrane antigen (PSMA)-targ

84 By study design, PET/CT scans were performed at baseline and before start

85 from the 4 institutions relying on different PET/CT scanners.

86 ality of lesion delineation in the different PET reconstructions was independently evaluated by 3 exp

87 l or negative or as oligometastatic disease (PET-1).

88 ased analysis, the sensitivity of (18)F-DOPA PET/CT in detecting soft-tissue and bone or bone-marrow

89 %, 75% and 54%, respectively, for (18)F-DOPA PET/CT.

90 ssessed as K(i)(cer) value using [(18)F]DOPA PET before and 6 weeks after antipsychotic discontinuati

91 thermore, they also underwent an [(18)F]DOPA PET scan to quantify striatal dopamine synthesis capacit

92 luorodihydroxyphenyl-l-alanine PET (18F-DOPA-PET) and resting state functional MRI (rs-fMRI).

93 ents were evaluated with gallium 68 DOTATATE PET/CT, and in cases of high-grade tumors, they were als

94 Conclusion: (64)Cu-DOTATATE PET/CT is a safe imaging technique that provides high-qu

95 rwent PET/CT scanning with a 120-min dynamic PET scan centered on the pancreas.

96 In vivo dynamic PET studies were performed on mice bearing U87 (CXCR4 lo

97 ility of [(18)F]FGlc-FAPI may allow extended PET studies of FAP-related diseases, such as cancer, but

98 edicated DDG approaches for axially extended PET, compared with DDG for conventional step-and-shoot s

99 We have installed a custom-fabricated PET insert into our small-animal MRI instrument and used

100 -treated EAE mice were imaged with (18)F-FAC PET to assess if this approach can monitor the effect of

101 Addition of (18)F-FACBC PET derived parameters (V(T), SUV) to DWI and RAFF deriv

102 Results: Compared with ceCT, (68)Ga-FAPI PET/CT results led to changes in TNM staging in 10 of 19

103 to assess the performance of full-dose (FD) PET image synthesis in both image and sinogram space fro

104 cation of glucose metabolic rates with 2-FDG PET, a method that permits the noninvasive assessment of

105 greements between whole-body DW MRI- and FDG PET/MRI-based response classifications with Krippendorff

106 o were untreated showed no change in any FDG PET or cardiac MRI parameter.

107 Patients underwent CT and (18)F-FDG PET at baseline and after 4 cycles (the first evaluation

108 ach was established and tested for (18)F-FDG PET brain imaging.

109 (18)F-FDG PET imaging shows these changes are accompanied by alter

110 o changed management compared with (18)F-FDG PET in 1 patient (1%; 95% CI, 0%-5%).

111 what higher sensitivity than CT or (18)F-FDG PET in lymph nodes (92.4% vs. 69.7% and 89.4%, respectiv

112 demonstrates lower conspicuity on (18)F-FDG PET than the more common invasive ductal carcinoma.

113 accuracy was reached by combining (18)F-FDG PET, amyloid PET, and nonimaging variables.

114 Amyloid PET, (18)F-FDG PET, and CSF test combinations may add accuracy to clini

115 al clinical settings, amyloid PET, (18)F-FDG PET, and MRI were highly sensitive for neuropathologic A

116 -weighted early-phase acquisition ((18)F-FDG PET-equivalent), a single scan potentially contains comp

117 (18)F-FDG PET/CT detected previously unidentified metastases in 8

118 End-of-treatment (EOT) (18)F-FDG PET/CT findings are variable among patients with negativ

119 FES PET/CT compared favorably with (18)F-FDG PET/CT for detection of metastases in patients with meta

120 uate the diagnostic performance of (18)F-FDG PET/CT for the detection of posttransplantation lymphopr

121 Conclusions (18)F-FDG PET/CT had high specificity for all IE subtypes; however

122 sify uptake patterns of whole-body (18)F-FDG PET/CT images in patients with lung cancer and lymphoma.

123 Results: Twenty-seven patients had (18)F-FDG PET/CT imaging at baseline and after at least 4 cycles p

124 for uniformity in conjunction with (18)F-FDG PET/CT imaging of mini image-quality phantoms designed t

125 ncer underwent baseline and repeat (18)F-FDG PET/CT imaging within 7 d.

126 overview of the current status of (18)F-FDG PET/CT in the monitoring of tumoral and systemic immune

127 ggest adding (18)F-FLT PET/CT when (18)F-FDG PET/CT is inconclusive or positive within the previously

128 The specificity of both CT and (18)F-FDG PET/CT is low because of radiation-induced changes.

129 Although (18)F-FDG PET/CT is widely available and is increasingly being use

130 ethods: One hundred forty baseline (18)F-FDG PET/CT scans were selected from U.K. and Dutch studies o

131 Our objective was to use (18)F-FDG PET/CT to identify a high-risk subgroup requiring therap

132 on tomography/computed tomography ((18)F-FDG PET/CT) has recently emerged as another IE imaging modal

133 Of 21 patients with UrC-ADC before (18)F-FDG PET/CT, Mayo staging was I/II in 8, III in 3, and IV in

134 41 patients, of whom 216 underwent (18)F-FDG PET/CT-guided biopsy and 125 underwent CT-guided biopsy.

135 d STS of the extremities underwent (18)F-FDG PET/MRI before and after ILP with melphalan and tumor ne

136 provide a rationale and overview of the FDG PET/CT Profile claims as well as its context, and to out

137 (18)FDG-PET/CT can visualize both inflammation and malignancy an

138 Use of 18F-FDG-PET/CT at the initial presentation of patients with susp

139 de of TRL-positive patients misleads 18F-FDG-PET/CT for detecting nodal metastasis.

140 sion tomography-computed tomography (18F-FDG-PET/CT) can be influenced by the increased glycolytic ac

141 equences, in which amyloid-PET and (18)F-FDG-PET are placed at different positions in the order of di

142 cose positron emission tomography ((18)F-FDG-PET).

143 Herein, we report a (18)F-FDG-PET/CT-based deep learning model, which demonstrates hig

144 Recent studies suggest that FDG-PET/CT could help discriminate between active and residu

145 These findings indicate [(18)F]FDOPA PET dopamine imaging has potential as biomarker to guide

146 Conclusion: (18)F-FES PET/CT compared favorably with (18)F-FDG PET/CT for dete

147 ; range, 6-44 d) and postoperative (18)F-FET PET (time after surgery: median, 14 d; range, 5-28 d) we

148 tabolic responders to ICI or TT on (18)F-FET PET had a significantly longer stable follow-up (thresho

149 Threshold values of (18)F-FET PET parameters to predict outcome were established by re

150 In all lesions, static and dynamic (18)F-FET PET parameters were obtained (i.e., mean tumor-to-brain

151 )F-fluorofuranylnorprogesterone ((18)F-FFNP) PET/CT imaging of tumor glucose metabolism and progester

152 ght stencil-printed electrodes on a flexible PET (polyethylene terephthalate) substrate is proposed f

153 ne and 1-year follow-up MRI and flortaucipir PET.

154 (18)F-flortaucipir PET alone may convey additional information equivalent t

155 mission tomography (PET), (18)F-flortaucipir PET, and adjusted hippocampal volume (aHCV).

156 The diagnostic impact of (18)F-FLT PET/CT was highest after cRT.

157 We suggest adding (18)F-FLT PET/CT when (18)F-FDG PET/CT is inconclusive or positive

158 d to define the role of (18)F-flubrobenguane PET, particularly in comparison to standard diagnostic p

159 st-processing methods for (18)F-Fluciclovine PET and multisequence multiparametric MRI in the predict

160 (Fig 2), and fluorine 18 fluorodeoxyglucose PET/CT (Fig 3) were performed.

161 valuated with fluorine 18 fluorodeoxyglucose PET/CT, with imaging findings reviewed as part of the sy

162 greement with fluorine 18 fluorodeoxyglucose PET/MRI for treatment response assessment in children an

163 sification of fluorine 18-fluorodeoxyglucose PET uptake patterns in foci suspicious and nonsuspicious

164 (18)F-fluorodeoxyglucose PET and CSF p-tau changes occurred later in the fourth d

165 Flurpiridaz PET was safe and well tolerated.

166 nil positron emission tomography ([(18)F]FMZ-PET) and GABA concentrations by using proton magnetic re

167 s increased in 1 of 10 and 7 of 10 cases for PET/static and PET/matched, respectively.

168 he clinical PCWG3 subtype was determined for PET versus CI by 3 masked readers.

169 imaging tools such as (89)Zr-Df-IAB22M2C for PET imaging is of prime importance to identify patients

170 8) F radionuclide incorporation required for PET imaging.

171 The cellular substrate for PET signal was identified using brain section immunostai

172 ored PET scans (n = 103), the 5-year TTP for PET-negative cases by Deauville criteria (D1-D3, DX) was

173 vasive clinical absolute quantification from PET/MR to PET/CT by allowing the accurate determination

174 Median DeltaSUV on i-PET was 86.2%.

175 Immuno-PET had a somewhat higher sensitivity than CT or (18)F-F

176 nstrate successful CD38-targeted immunologic PET imaging of multiple myeloma in a murine model and in

177 0.4%) in the CT group and 5 of 216 (2.3%) in PET group (P = 0.001).

178 l networks were trained to segment organs in PET/CT acquisitions (training CTs: 8,632, validation CTs

179 The distance between tumor positions in PET and CT were characterized in visual interpretation b

180 information associated with fully integrated PET/MRI.

181 d to assess agreement between intraprostatic PET/CT findings and histopathologic findings.

182 image and sinogram space from low-dose (LD) PET images and sinograms without sacrificing diagnostic

183 gy studies, cross-sectional and longitudinal PET-only studies, and comparative PET and autopsy studie

184 modalities, including radiography, CT, MRI, PET/CT, and US.

185 2 patients, the coregistration of multimodal PET/MRI tumor data was improved by using the reverse pha

186 tablished coronary artery disease, (18)F-NaF PET provides powerful independent prediction of fatal or

187 Results: (18)F-NaF PET/CT scans from 219 patients with PCa were included, o

188 Methods: (18)F-NaF PET/CT scans were retrieved from all patients who partic

189 ver agreement in (18)F-sodium fluoride (NaF) PET/CT for the detection of bone metastases in patients

190 (18)F-flurpiridaz is a novel PET MPI agent with superior image and defect resolution.

191 in tumor perfusion measured with (15)O-H(2)O PET after only 14 d of therapy showed an association wit

192 xtensive simulation studies, the analyses of PET-imaging outcomes from the Alzheimer's Disease Neuroi

193 be proposed as the standardized criterion of PET complete metabolic response, confirming the value of

194 Finally, the reproducibility of PET measurements from test and retest scans was assessed

195 n of many cooperative groups in the study of PET-guided therapy.

196 nt lesions were missed in 1.2% (12/1,003) on PET/MRI, leading to a change in TNM staging in 0.5% (5/1

197 lated in the tumor lesions, as also shown on PET/CT imaging using (68)Ga-FAPI-46.

198 nowpit from the Austrian Alps; however, only PET was detected in the nanometer range for both snowpit

199 Finally, visual inspection of (18)F-PM-PBB3-PET images was indicated to facilitate individually base

200 PERCIST and immunotherapy-modified PERCIST, PET-based response maintained prognostic significance in

201 abeling an anti-ICOS antibody and performing PET scanning.

202 argeted imaging with zirconium 89-pertuzumab PET/CT was successful in detecting HER2-positive metasta

203 Deep learning-corrected PET (PET(DL)) images were quantitatively evaluated by using t

204 , neuroinflammation (measured by 11C-PK11195 PET) and brain atrophy (derived from structural MRI) pre

205 en combined with 5-PS assessment, a positive PET-2 result was highly predictive of treatment failure.

206 Therefore, [(11)C]13 is a potential PET imaging ligand for mGluR2 in different central nervo

207 pivotal role, standardization of preclinical PET/CT protocols, including CT absorbed dose guidelines,

208 The quality of the predicted PET images was assessed by 2 nuclear medicine specialist

209 Because previous PET studies in HCC have been hampered by high background

210 -to-1 Prism-PET module, and one 9-to-1 Prism-PET module) to introduce intercrystal light sharing, whi

211 uniform glass light-guide, one 4-to-1 Prism-PET module, and one 9-to-1 Prism-PET module) to introduc

212 By comparison, the 4-to-1 coupled Prism-PET module achieved a DOI resolution of 2.5 mm FWHM and

213 dition to the standard imaging in Ga-68 PSMA PET/CT, particularly in patients presenting for restagin

214 Management after PSMA PET was recorded but not mandated.

215 The combined use of SN biopsy and PSMA PET/CT identified all pN1 patients (100% sensitivity; 95

216 Conclusion: PSMA PET results are highly predictive of FFP at 3 y in men u

217 29% of patients, all lesions on (68)Ga-PSMA PET resolved in response to treatment.

218 5477), 69 mPC patients underwent (68)Ga-PSMA PET/CT before bone biopsy.

219 nd accuracy for LNM detection on (68)Ga-PSMA PET/CT in the PLND cohort were 30.6%, 96.5%, 68.8%, 84.5

220 Multiphasic (68)Ga-PSMA PET/CT led to a better determination of equivocal findin

221 Also, (68)Ga-PSMA PET/CT positivity was correlated with clinical parameter

222 However, whether and how PSMA PET/CT affects the management of patients undergoing sca

223 W2 criteria but adds value by including PSMA PET criteria.

224 irty-two percent of men with a negative PSMA PET result did not receive treatment.

225 In particular, men with negative PSMA PET results or disease identified as still confined to t

226 ing SN biopsy in patients with negative PSMA PET/CT results increased the combined sensitivity to 100

227 ifferent criteria for interpretation of PSMA PET were published: the European Association of Nuclear

228 Yet, the implications of PSMA PET-derived whole-body tumor volume for overall survival

229 DR was calculated as the proportion of PSMA PET-positive patients to all patients independent of the

230 y or correlative imaging within 3 mo of PSMA PET.

231 ents without suspected LN metastases on PSMA PET/CT were considered candidates for SN biopsy with ind

232 tients who had at least 1 true-positive PSMA PET lesion localized that corresponded with the referenc

233 Conclusion: PSMA(TV50) is a promising PSMA PET biomarker that is reproducible and easily quantified

234 the Roach formula and compared with the PSMA PET/CT results.

235 ly prostate-specific membrane antigen (PSMA) PET findings, are not considered.

236 )F prostate-specific membrane antigen (PSMA) PET/CT, a newer examination, is unclear.

237 reproducibility in evaluating (68)Ga-PSMA11 PET, there are some factors causing interreader disagree

238 n radiation doses were extrapolated from rat PET data.

239 Methods: Tumors extracted from real PET/CT scans of patients with non-small cell lung cancer

240 Methods: High-resolution PET detector modules were fabricated with single-ended r

241 ucted to explore the potential of (68)Ga-RGD PET/CT imaging for guiding current treatment decisions a

242 For those with Deauville (D)-scored PET scans (n = 103), the 5-year TTP for PET-negative cas

243 In pre- and post-SLND PET comparison, 10 of 16 had at least one lesion already

244 currence), and 2 had no disease on post-SLND PET.

245 Conclusion: Microdose (11)C-sorafenib PET did not predict intratumoral sorafenib concentration

246 11)C-(S)-NR2B-SMe has adequate NR2B-specific PET signal in rat brain to warrant further evaluation in

247 nsfer fluorescence correlation spectroscopy (PET-FCS) to show how a small alpha-helical domain, the N

248 These data suggest PET at 2 h after oral (18)F-FDG administration should yi

249 rmine whether imaging with the HER2-targeted PET tracer zirconium 89 ((89)Zr)-pertuzumab can depict H

250 te-specific membrane antigen (PSMA)-targeted PET agent, in patients with biochemically relapsed prost

251 e-specific membrane antigen (PSMA)-targeting PET imaging is becoming the reference standard for prost

252 sy), EUS, CT or MRI, and/or (68)Ga-DOTA-TATE PET/CT.

253 Tau PET was a significant mediator CBF/sPDGFRbeta-MoCA relat

254 hort where the correlation with 18F-GTP1 tau PET was evaluated (Alzheimer's disease = 38, control = 1

255 imer's disease are different for MRI and tau-PET and may differ across phenotypes, particularly for M

256 ification of six polyethylene terephthalate (PET) and four polybutylene terephthalate (PBT) oligomers

257 Polyethylene terephthalate (PET) is selectively depolymerized by a carbon-supported

258 f microplastics (polyethylene terephthalate (PET), polyvinyl chloride, and polypropylene carbonate),

259 The PET radioligand (68)Ga-DO3A-VS-Tuna-2 ((68)Ga-Tuna-2) wa

260 The PET radiotracer (18)F-(2S,4R)4-fluoroglutamine ((18)F-Gl

261 CD8-IHC confirmed the PET imaging results.

262 ate determination of motion vectors from the PET data itself.

263 Weekly blood samples through 100 days in the PET group were tested for HHV-6 viremia using a real-tim

264 : Of 609 DLBCL patients participating in the PET-Guided Therapy of Aggressive Non-Hodgkin Lymphomas t

265 aluate the correlation between uptake of the PET ligand (68)Ga-NOTA-AE105, targeting the urokinase-ty

266 gents were evaluated for their impact on the PET brain imaging data.

267 nge in TNM staging in 2.9% (29/1,003) due to PET/MRI.

268 nical absolute quantification from PET/MR to PET/CT by allowing the accurate determination of motion

269 (FDG) and simultaneous time-of-flight (TOF) PET/MRI with hippocampal subfield analysis of AD, mild c

270 portant cancer positron emission tomography (PET) agent [(18)F]5-fluorouracil ([(18)F]FU).

271 1)C]-LY2795050 positron emission tomography (PET) as a predictor of response to naltrexone.

272 ards this end, positron emission tomography (PET) imaging has emerged as one of the most informative

273 maceutical for positron emission tomography (PET) imaging that is used to image Parkinson's disease,

274 ve MOR agonist positron emission tomography (PET) radioligand, to investigate endogenous opioid tone

275 ects underwent positron emission tomography (PET) scans with two different radiotracers at baseline p

276 F-florbetaben) positron emission tomography (PET), (18)F-flortaucipir PET, and adjusted hippocampal v

277 Using positron emission tomography (PET), we identified the dorsal striatum as the brain are

278 ing results of positron emission tomography (PET)-directed treatment approaches, we designed a Nation

279 py (NIRS), and positron-emission tomography (PET).

280 yglucose (FDG) positron emission tomography (PET)/computed tomography (CT) is currently the standard

281 myloid and tau positron emission tomography [PET]) structural magnetic resonance imaging (MRI), and r

282 orrelation between AIs of Abeta PET and TSPO PET in 4 investigated Abeta mouse models (APP/PS1: R = 0

283 here was a significant increase in the tumor PET signal in PEGPH20-treated PDX animals, and this sign

284 Of 150, 97 underwent PET; 22 of the 97 (mean age, 71 years +/- 6; 13 women) w

285 Individuals underwent PET/CT scanning with a 120-min dynamic PET scan centered

286 nto our small-animal MRI instrument and used PET/MRI hybrid imaging to define regions of amyloid vuln

287 We used PET in vivo with (i) 11C-PK-11195, a marker of activated

288 Next, we used PET/MRI to define uptake in six brain regions.

289 ent data from a retrospective analysis using PET/CT and PET/MRI examinations to investigate the effic

290 , NCNs have been successfully captured using PET with (18)F-FDG.

291 The first Biograph Vision PET/CT system (Siemens Healthineers) was installed at th

292 In May 2018, the Biograph Vision PET/CT system was installed at the University Medical Ce

293 64)Cu-LLP2A uptake, as quantified by in vivo PET (R = 0.69, P < 0.01).

294 : Among 668 patients, we selected 27 in whom PET/CT results obtained with (68)Ga-PSMA-11, (18)F-DCFPy

295 xcellently reproduced (166 with CT; 164 with PET; and 164 with MRI).

296 net cost-savings per patient associated with PET was $8,707 compared to prophylaxis.

297 that multicancer blood testing combined with PET-CT can be safely incorporated into routine clinical

298 In visual comparison with PET/ex, the rate of good alignment was increased in 1 of

299 -Deoxy-2-(18)F-fluoro-d-glucose (2-FDG) with PET is undeniably useful in the clinic, being able, amon

300 ty of alpha7-nAChR in the brain in vivo with PET.